Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EWSR1
REST API REST API
Homo sapiens
EWSR1 is differentially expressed in 309 experiments: 160 organism parts: testis, bone marrow, ... (158 more);, 262 disease states: normal, prostate carcinoma, ... (260 more);, 100 cell types 421 cell lines 45 compound treatments and 83 other conditions.
Synonyms EWS
Orthologs A8E651_BOVIN (Bos taurus)   Ewsr1 (Rattus norvegicus)   Ewsr1 (Mus musculus)   ewsr1a (Danio rerio)   ewsr1b (Danio rerio)   GAR1 (Saccharomyces cerevisiae)   EWSR1 (Gallus gallus)   caz (Drosophila melanogaster)   CG14718 (Drosophila melanogaster)   ewsr1 (Xenopus laevis)   ENSCAFG00000018550 (Canis familiaris)   LOC607046 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, regulation of transcription, DNA-dependent, cytoplasm, intracellular, metal ion binding, nucleic acid binding, calmodulin binding, nucleus, nucleotide binding, RNA binding, zinc ion binding
InterPro Term Znf_RanBP2, RRM_dom
UniProt Accession Q96FE8, Q96MX4, C9JGE3, B0QYK0, B0QYK1, B0QYJ3, B0QYJ4, B0QYJ5, B0QYJ7, B0QYJ6, Q9BWA2, Q01844, F8WC90
Gene-Disease Assocation HISTIOCYTOMA, ANGIOMATOID FIBROUS, EWING SARCOMA; ES
Search EB-eye ENSG00000182944
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
HL-60
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258
BT-474
2
E-GEOD-5823, E-GEOD-3529
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HCC38
2
E-MTAB-37, E-MTAB-62
KG1
2
E-MTAB-37, E-GEOD-24147
415 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21750, ... (50 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-26672
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
naive T cell
1
E-GEOD-1460
neuroblastoma cell
1
E-MEXP-669
secretory cell
1
E-GEOD-3998
94 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-GEOD-12254, ... (65 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MEXP-2034, E-MTAB-62, E-MTAB-37, E-GEOD-5377
glioblastoma
3
E-MTAB-37, E-GEOD-6014, E-GEOD-4290
T-cell acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-1577
embryonal rhabdomyosarcoma
2
E-MTAB-62, E-MEXP-121
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
256 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (27 experiments)

Factor Value U/D Experiments
none
4
6
E-GEOD-5824, E-MEXP-1601, E-MEXP-1958, E-GEOD-412, E-TABM-868, ... (10 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
hydrogen peroxide
1
E-GEOD-5339
5-aza-2'-deoxycytidine + trichostatin A
1
E-MEXP-1269
cadmium chloride 2.5-hydrate
1
E-GEOD-6907
1,2,4-benzenetriol
1
1
E-GEOD-7664
39 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-GEOD-19348, ... (12 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (6 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-21750, E-TABM-321, E-TABM-43, E-TABM-868, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-MEXP-1446, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-MEXP-2069, E-GEOD-1926, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-TABM-43, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.406 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM